Assay Detail
Binding
CHEMBL4266249
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Inhibition of wild type EML4/ALK C1156Y mutant (unknown origin) expressed in NIH/3T3 cells
2
Total Activities
2
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Binding |
| Organism | Homo sapiens |
| Confidence | 7 — Homologous single protein target |
| Curated By | Intermediate |
Publication
First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 2 | 7.56 | 8.80 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL3286830 | LORLATINIB | 4.0 | 1 | 8.80 |
| CHEMBL601719 | CRIZOTINIB | 4.0 | 1 | 6.32 |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL3286830 | LORLATINIB | IC50 | = | 1.6 | nM | 8.80 |
| CHEMBL601719 | CRIZOTINIB | IC50 | = | 478.0 | nM | 6.32 |